Equities

Pharmx Technologies Ltd

PHX:ASX

Pharmx Technologies Ltd

Actions
TechnologyTechnology
  • Price (AUD)0.031
  • Today's Change0.00 / 0.00%
  • Shares traded8.34k
  • 1 Year change-24.39%
  • Beta1.5221
Data delayed at least 20 minutes, as of May 09 2024 01:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PharmX Technologies Limited, formerly Corum Group Limited, is an Australian company that operates a network connecting retail pharmacies and suppliers in Australia and New Zealand. The Company offers PharmX, an electronic gateway that links pharmacies, pharmaceutical wholesalers and direct suppliers within the pharmacy market, and PharmXchange, a digital sales and marketing platform integrated with PharmX. The Company is also focused on creating a more productive environment for pharmacy and suppliers, with additional ordering functions, such as stock checks, credits, and auto account set up direct from their point of sale (POS) system.

  • Revenue in AUD (TTM)3.24m
  • Net income in AUD-76.00k
  • Incorporated1950
  • Employees109.00
  • Location
    Pharmx Technologies LtdLevel 3, 120 Sussex StreetSYDNEY 2000AustraliaAUS
  • Phone+61 29289-4699
  • Fax+61 28069-0691
  • Websitehttps://www.corumgroup.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
XPON Technologies Group Ltd10.66m-7.58m5.00m90.00------0.4694-0.025-0.03470.0351-0.00430.8027--2.35118,452.90-57.09---195.31--71.71---71.13----------13.22---36.55------
Dxn Ltd6.45m-10.10m6.47m29.00------1.00-0.0877-0.07130.0552-0.00140.32443.204.76---50.79-33.88-110.06-40.3160.5635.15-156.58-113.871.26-2.151.03---59.4924.52-38.25---8.79--
RocketBoots Ltd744.87k-2.34m7.43m--------9.98-0.0397-0.03970.0126-0.01090.3849--6.30---121.06---426.44--54.36---314.49-----------16.84---67.65------
X2M Connect Ltd14.72m-6.85m10.14m--------0.6884-0.0317-0.03170.0682-0.00341.0523.186.15---48.86---296.32--29.75---46.56--0.698-10.851.21--56.08--36.36------
FinTech Chain Ltd10.43m220.46k11.06m133.0050.15--25.011.060.00030.00030.016-0.00261.5474.032.4278,456.951.997.5050.9952.0842.2448.761.304.661.082.471.70---9.4142.23-398.81---40.92--
Pharmx Technologies Ltd3.24m-76.00k18.55m109.00--1.1622.795.73-0.0001-0.00370.00540.02680.1099--2.93---0.2578-3.19-0.3552-4.2468.8686.80-2.35-8.76--4.460.0178--13.78-13.38-574.05---0.585--
Senetas Corp Ltd27.89m-8.09m25.14m83.00--1.92--0.9014-0.0066-0.00660.02270.00840.8410.72753.99336,036.50-47.88-20.02-66.38-29.2985.9282.63-56.93-29.691.01-41.460.4345--16.838.62-24.12---16.39--
Spirit Technology Solutions Ltd116.86m-8.80m60.13m36.00--0.6639--0.5146-0.0122-0.01220.16270.06630.972621.079.98---7.33-14.39-10.12-19.4145.7651.66-7.53-15.760.848-2.520.429---6.0850.9978.58---27.43--
Data as of May 09 2024. Currency figures normalised to Pharmx Technologies Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Invesense Asset Management Ltd.as of 29 Feb 202490.52k0.02%
Data from 29 Feb 2024 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.